BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

EC approves Zeposia ozanimod for relapsing-remitting MS The European Commission approved Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY) to treat relapsing-remitting multiple sclerosis (RRMS). FDA approved the S1P receptor modulator in March for relapsing...
BioCentury | Apr 3, 2020
Distillery Therapeutics

Depletion of the mitochondrial chaperone HspA9 for BRAF-mutant melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Reducing production of the mitochondrial chaperone HspA9 could treat BRAF-mutant melanoma. In melanoma patients, high tumor levels of HspA9 mRNA were associated with poor survival. In two human melanoma cell...
BioCentury | Nov 21, 2019
Tools & Techniques

Measuring real-time PK/PD by monitoring aberrant chaperone activity

A Memorial Sloan Kettering Cancer Center team developed an imaging probe for aberrant protein networks that could guide more optimal drug dosing and scheduling earlier in development. In cancer, tumor biopsy collection as well as...
BioCentury | Nov 14, 2019
Targets & Mechanisms

New roles for HDACs in the cytoplasm and muscle disorders

While HDACs are known for their epigenetic function, NIBR researchers have discovered cytoplasmic HDAC4 substrates involved in muscle physiology. The findings suggest blocking HDAC4 deacetylation activity could treat muscle atrophy and other musculoskeletal disorders. HDACs...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

...lung cancer (NSCLC) 4362 Protein folding Protein folding DNAJ; AR-V7 DNAJ isoforms AR-V7-expressing CRPC 2901 HSPA4...
BioCentury | Oct 24, 2017
Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Mouse and fruit fly studies suggest promoting HspA8 expression could help treat ALS. In muscle samples from mouse and Drosophila models of ALS overexpressing TDP-43 with the ALS-associated point mutations...
BioCentury | Oct 13, 2017
Financial News

Intezyne raises $10M in series A

On Oct. 6, Intezyne Technologies Inc. (Tampa, Fla.) raised $10 million in an oversubscribed series A round led by existing investor Gaston Capital Healthcare Fund (GCHF). Undisclosed high-net-worth investors and family offices also participated. CFO...
BioCentury | Oct 6, 2017
Financial News

Intezyne raises $10M series A

Intezyne Technologies Inc. (Tampa, Fla.) raised $10 million in an oversubscribed series A round led by existing investor Gaston Capital Healthcare Fund (GCHF). Undisclosed high-net-worth investors and family offices also participated. CFO E. Russell McAllister...
BioCentury | Aug 17, 2017
Targets & Mechanisms

GRP-THINK AT THE BBB

Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development....
BioCentury | Jun 29, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

...with Usher syndrome Type II. ProQR Therapeutics N.V. (NASDAQ:PRQR) Pipeline Information Biomarkers Cancer Liver cancer Heat shock protein family A member 4 (HspA4)...
...factor 19 (FGF19), which predicted poor overall survival, also correlated with high expression levels of HspA4...
Items per page:
1 - 10 of 45